Methods for relieving asthma-associated airway hyperresponsiveness
    2.
    发明授权
    Methods for relieving asthma-associated airway hyperresponsiveness 失效
    缓解哮喘相关气道高反应性的方法

    公开(公告)号:US08679499B2

    公开(公告)日:2014-03-25

    申请号:US12697882

    申请日:2010-02-01

    摘要: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.

    摘要翻译: 与NKT细胞抗原受体和其对应的抗原呈递分子相互作用,但抑制NKT细胞免疫功能的分子被施用于患者。 特别感兴趣的病症包括治疗系统性红斑狼疮(SLE),癌症,动脉粥样硬化和过敏性疾病。 在本发明的一些实施方案中,所述抑制剂是抗过敏糖脂,例如β-半乳糖神经酰胺。 提供了这种糖脂的药物制剂,并且可用于治疗涉及不期望的NKT细胞活化的疾病。

    Methods for inhibition of NKT cells
    3.
    发明授权
    Methods for inhibition of NKT cells 失效
    抑制NKT细胞的方法

    公开(公告)号:US07682614B2

    公开(公告)日:2010-03-23

    申请号:US11266033

    申请日:2005-11-02

    IPC分类号: A61K31/7028 A61K39/395

    摘要: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.

    摘要翻译: 与NKT细胞抗原受体和其对应的抗原呈递分子相互作用,但抑制NKT细胞免疫功能的分子被施用于患者。 特别感兴趣的病症包括治疗系统性红斑狼疮(SLE),癌症,动脉粥样硬化和过敏性疾病。 在本发明的一些实施方案中,所述抑制剂是抗过敏糖脂,例如β-半乳糖神经酰胺。 提供了这种糖脂的药物制剂,并且可用于治疗涉及不期望的NKT细胞活化的疾病。

    METHODS FOR INHIBITION OF NKT CELLS
    4.
    发明申请
    METHODS FOR INHIBITION OF NKT CELLS 失效
    NKT细胞抑制方法

    公开(公告)号:US20100197613A1

    公开(公告)日:2010-08-05

    申请号:US12697882

    申请日:2010-02-01

    摘要: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.

    摘要翻译: 与NKT细胞抗原受体和其对应的抗原呈递分子相互作用,但抑制NKT细胞免疫功能的分子被施用给患者。 特别感兴趣的病症包括治疗系统性红斑狼疮(SLE),癌症,动脉粥样硬化和过敏性疾病。 在本发明的一些实施方案中,所述抑制剂是抗过敏糖脂,例如β-半乳糖神经酰胺。 提供了这种糖脂的药物制剂,并且可用于治疗涉及不期望的NKT细胞活化的疾病。